HUE047626T2 - Ciklin-függõ, fehérje kináz inhibitor hidroxietil-szulfonátja, annak kristályos formája és elõállítására szolgáló eljárás - Google Patents

Ciklin-függõ, fehérje kináz inhibitor hidroxietil-szulfonátja, annak kristályos formája és elõállítására szolgáló eljárás

Info

Publication number
HUE047626T2
HUE047626T2 HUE16746062A HUE16746062A HUE047626T2 HU E047626 T2 HUE047626 T2 HU E047626T2 HU E16746062 A HUE16746062 A HU E16746062A HU E16746062 A HUE16746062 A HU E16746062A HU E047626 T2 HUE047626 T2 HU E047626T2
Authority
HU
Hungary
Prior art keywords
cyclin
preparation
crystalline form
protein kinase
kinase inhibitor
Prior art date
Application number
HUE16746062A
Other languages
English (en)
Inventor
Guaili Wu
Xiaohui Gao
Junlei Jia
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of HUE047626T2 publication Critical patent/HUE047626T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE16746062A 2015-02-03 2016-01-12 Ciklin-függõ, fehérje kináz inhibitor hidroxietil-szulfonátja, annak kristályos formája és elõállítására szolgáló eljárás HUE047626T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510056995 2015-02-03

Publications (1)

Publication Number Publication Date
HUE047626T2 true HUE047626T2 (hu) 2020-05-28

Family

ID=56563428

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16746062A HUE047626T2 (hu) 2015-02-03 2016-01-12 Ciklin-függõ, fehérje kináz inhibitor hidroxietil-szulfonátja, annak kristályos formája és elõállítására szolgáló eljárás

Country Status (19)

Country Link
US (2) US10030018B2 (hu)
EP (1) EP3255046B1 (hu)
JP (1) JP6920993B2 (hu)
CN (1) CN106661025B (hu)
AU (1) AU2016214897B9 (hu)
CA (1) CA2974021A1 (hu)
CY (1) CY1122514T1 (hu)
DK (1) DK3255046T3 (hu)
ES (1) ES2764139T3 (hu)
HR (1) HRP20192286T1 (hu)
HU (1) HUE047626T2 (hu)
LT (1) LT3255046T (hu)
MX (1) MX2017009270A (hu)
PL (1) PL3255046T3 (hu)
PT (1) PT3255046T (hu)
RS (1) RS59782B1 (hu)
SI (1) SI3255046T1 (hu)
TW (1) TWI706951B (hu)
WO (1) WO2016124067A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN109384767B (zh) * 2017-08-08 2020-05-05 江苏恒瑞医药股份有限公司 一种吡啶并嘧啶类衍生物的制备方法及其中间体
US20210196719A1 (en) 2018-05-23 2021-07-01 Jiangsu Hengrui Medicine Co., Ltd. Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseases
CN110790748B (zh) * 2018-08-02 2022-04-19 江苏豪森药业集团有限公司 细胞周期蛋白依赖性激酶抑制剂的对甲苯磺酸盐晶型及其制备方法和用途
US10857146B2 (en) 2018-08-21 2020-12-08 Jiangsu Hengrui Medicine Co., Ltd. Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor
AU2020214930A1 (en) 2019-01-30 2021-09-16 Jiangsu Hengrui Medicine Co., Ltd. Use of composition containing CDK4/6 inhibitor in combination with anastrozole in preparation of medicament for treating tumor diseases
WO2021063332A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648889B1 (en) * 2003-07-11 2008-10-29 Warner-Lambert Company LLC Isethionate salt of a selective cdk4 inhibitor
BRPI0716880A2 (pt) * 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
CN104470921B (zh) 2013-05-17 2017-05-03 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
US20180009804A1 (en) 2018-01-11
PT3255046T (pt) 2020-01-06
RS59782B1 (sr) 2020-02-28
CN106661025A (zh) 2017-05-10
US10030018B2 (en) 2018-07-24
US10160759B2 (en) 2018-12-25
TWI706951B (zh) 2020-10-11
LT3255046T (lt) 2020-01-10
HRP20192286T1 (hr) 2020-03-20
AU2016214897B2 (en) 2020-05-21
EP3255046A4 (en) 2018-10-10
CY1122514T1 (el) 2021-01-27
ES2764139T3 (es) 2020-06-02
CN106661025B (zh) 2019-08-16
MX2017009270A (es) 2017-10-11
AU2016214897A1 (en) 2017-08-10
TW201629060A (zh) 2016-08-16
EP3255046A1 (en) 2017-12-13
CA2974021A1 (en) 2016-08-11
EP3255046B1 (en) 2019-11-27
WO2016124067A1 (zh) 2016-08-11
SI3255046T1 (sl) 2020-02-28
US20180230147A1 (en) 2018-08-16
JP2018503634A (ja) 2018-02-08
DK3255046T3 (da) 2020-01-20
JP6920993B2 (ja) 2021-08-18
AU2016214897B9 (en) 2020-06-04
PL3255046T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
HK1243419B (zh) 一種btk激酶抑制劑的結晶形式及其製備方法
LT3255046T (lt) Nuo ciklino priklausančio baltymo kinazės inhibitoriaus hidroksietilo sulfonatas, jo kristalinė forma ir jos gavimo būdas
PL3218378T3 (pl) Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
HK1253537A1 (zh) 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法
IL250318B (en) Protein kinase c inhibitors and methods of using them
HK1258996A1 (zh) 新型fyn激酶抑制劑的方法、組合物以及用途
PL3447051T3 (pl) Sposób otrzymywania inhibitora kinazy tyrozynowej i jego pochodnej
EP3376870A4 (en) PROCESS FOR PREPARING KINASE INHIBITORS AND INTERMEDIATES THEREOF
ZA201808014B (en) Adenine derivatives as protein kinase inhibitors
ZA201802141B (en) Egfr kinase inhibitor and preparation method and use thereof
EP3265093A4 (en) Tricyclic kinase inhibitors of melk and methods of use
ZA201808238B (en) Certain protein kinase inhibitors
LT3327012T (lt) Bilastino kristalinės formos ir jų gamybos būdai
EP3193874A4 (en) Crystalline forms of tyrosine kinase inhibitors and their salts
EP3572415C0 (en) JAK KINASE INHIBITOR, PREPARATION METHOD AND USE THEREOF
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors